RDY

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

Dollar change +0.12
Percentage change 0.85	%

Peers: TEVA JNJ NVS ABBV PFE MRK BMY LLY SNY GSK

| Held by: VWO SPEM VXUS AVEM DFAE VEU DFEM DFAX APIE KOMP

Index	-	P/E	18.67	EPS (ttm)	0.77	Insider Own	0.00%	Shs Outstand	834.09M	Perf Week	1.56%
Market Cap	11.94B	Forward P/E	17.56	EPS next Y	0.82	Insider Trans	-	Shs Float	834.06M	Perf Month	-6.26%
Income	639.71M	PEG	25.33	EPS next Q	0.21	Inst Own	14.46%	Short Float	1.28%	Perf Quarter	-13.20%
Sales	3.60B	P/S	3.32	EPS this Y	2.17%	Inst Trans	-	Short Ratio	12.93	Perf Half Y	0.93%
Book/sh	4.37	P/B	3.28	EPS next Y	-0.22%	ROA	13.14%	Short Interest	10.68M	Perf Year	4.94%
Cash/sh	0.90	P/C	15.87	EPS next 5Y	0.74%	ROE	19.12%	52W Range	12.90 - 16.89	Perf YTD	2.90%
Dividend Est.	0.10 (0.68%)	P/FCF	87.16	EPS past 5Y	20.07%	ROI	17.14%	52W High	-15.23%	Beta	0.54
Dividend TTM	0.10 (0.67%)	Quick Ratio	1.36	Sales past 5Y	8.97%	Gross Margin	57.16%	52W Low	11.01%	ATR (14)	0.29
Dividend Ex-Date	Jul 30, 2024	Current Ratio	1.92	EPS Y/Y TTM	3.31%	Oper. Margin	21.92%	RSI (14)	40.02	Volatility	1.62% 1.79%
Employees	27048	Debt/Eq	0.16	Sales Y/Y TTM	10.96%	Profit Margin	17.79%	Recom	2.89	Target Price	16.17
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-16.39%	Payout	10.00%	Rel Volume	1.93	Prev Close	14.20
Sales Surprise	3.61%	EPS Surprise	-13.57%	Sales Q/Q	14.98%	Earnings	Nov 05 AMC	Avg Volume	826.06K	Price	14.32
SMA20	-2.02%	SMA50	-6.45%	SMA200	-5.69%	Trades		Volume	1,597,204	Change	0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-11-24	Downgrade	Jefferies	Buy → Underperform
Aug-29-23	Downgrade	HSBC Securities	Buy → Hold
May-18-23	Downgrade	Bernstein	Outperform → Mkt Perform
Mar-17-23	Upgrade	BofA Securities	Neutral → Buy
Jan-30-23	Initiated	JP Morgan	Underweight
Nov-14-22	Downgrade	Credit Suisse	Neutral → Underperform
Jan-03-22	Resumed	BofA Securities	Neutral
Jul-27-21	Downgrade	Credit Suisse	Outperform → Neutral
Feb-02-21	Upgrade	Barclays	Equal Weight → Overweight	$56 → $70
Sep-18-20	Upgrade	Investec	Sell → Hold
Sep-18-20	Upgrade	BofA Securities	Neutral → Buy
Jan-28-20	Downgrade	CLSA	Buy → Outperform
Jan-27-20	Downgrade	CLSA	Buy → Outperform
Jan-09-20	Upgrade	Citigroup	Sell → Buy
Nov-04-19	Downgrade	BofA/Merrill	Buy → Neutral
Sep-04-19	Upgrade	Credit Suisse	Underperform → Outperform
Jul-01-19	Upgrade	Macquarie	Neutral → Outperform
Jun-20-19	Initiated	Deutsche Bank	Hold
Jun-11-19	Initiated	Barclays	Equal Weight	$39
May-20-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight

Show Previous Ratings

Nov-20-24 08:30AM	Dr. Reddys Gains Strong Rating Amid Robust Growth (TipRanks)
Nov-07-24 06:31AM	Dr. Reddys Labs Releases Unaudited Financial Results (TipRanks)
Nov-06-24 02:15AM	Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-05-24 02:23PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
09:59AM	Dr. Reddys Q2 & H1FY25 Financial Results (Business Wire)
07:59PM	Loading…
Oct-29-24 07:59PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Oct-25-24 07:40AM	Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year (Business Wire)
Oct-14-24 09:47AM	Dr. Reddys Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month (Business Wire)
Oct-09-24 07:57AM	Dr. Reddys Subsidiary Triumphs in CAR-T Cell Therapy Trial (TipRanks)
03:58AM	Dr. Reddys Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years (Insider Monkey)
Oct-08-24 11:32AM	Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for Indias First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma (Business Wire)
06:27AM	Dr. Reddys Unveils New Danish Subsidiary (TipRanks)
Oct-02-24 11:10AM	Dr. Reddys signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries (Business Wire)
Oct-01-24 07:14AM	Dr. Reddys Acquires Global NRT Leader Nicotinell (TipRanks)
Sep-28-24 12:57PM	Dr. Reddys Expands Portfolio with $620M Investment (TipRanks)
06:13AM	Loading…
Aug-21-24 06:13AM	Dr Reddys, Aurigene and Kainomyx to co-develop anti-malarials (Pharmaceutical Technology)
Aug-20-24 02:42PM	Dr. Reddys Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug (Business Wire)
Jul-29-24 01:01PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
11:55AM	Dr. Reddys Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar (Business Wire)
10:07AM	Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat (Zacks)
Jul-27-24 09:51AM	Dr. Reddys Q1FY25 Financial Results (Business Wire)
Jun-27-24 10:25AM	Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug (Zacks)
Jun-26-24 03:31PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
11:26AM	Dr. Reddys to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business (Business Wire)
Jun-03-24 01:05PM	Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities (Business Wire)
May-28-24 09:53AM	Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America (Business Wire)
May-22-24 12:16PM	Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar (Zacks)
07:11AM	Alvotech and Dr Reddys partner to commercialise AVT03 (Pharmaceutical Technology)
May-21-24 10:05AM	Alvotech and Dr. Reddys Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia & Xgeva in the U.S., Europe and UK (Business Wire)
May-09-24 09:40AM	Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term (Zacks)
01:55PM	Loading…
May-08-24 01:55PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
01:12PM	Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Call Transcript (Insider Monkey)
09:01AM	Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow (Zacks)
May-07-24 12:54PM	RDY Stock Earnings: Dr Reddy's Laboratories Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
10:31AM	Dr. Reddys Q4 & Full Year FY24 Financial Results (Business Wire)
May-03-24 08:00AM	Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. (Business Wire)
Mar-22-24 07:00AM	Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India (GlobeNewswire)
Mar-20-24 09:40AM	Here's Why Doctor Reddy's (RDY) is a Strong Value Stock (Zacks)
Mar-19-24 07:00AM	Dr. Reddy's Laboratories launches Versavo (bevacizumab) in the UK (Business Wire)
Feb-28-24 09:40AM	Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term (Zacks)
Feb-05-24 09:50AM	Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term (Zacks)
Feb-01-24 11:01AM	Dr. Reddys Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript (Insider Monkey)
09:03AM	Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Jan-31-24 09:44AM	Dr. Reddys Q3 & 9M FY24 Financial Results (Business Wire)
Jan-30-24 02:03PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
06:19AM	UPDATE 1-Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businesses (Reuters)
05:38AM	India's Dr Reddy's beats Q3 profit estimates on strong US sales (Reuters)
Jan-29-24 05:50PM	Indias Sensex Declines, Weighed by Financial Stocks (The Wall Street Journal)
Jan-03-24 06:00AM	Dr. Reddy's Announces the Acquisition of MenoLabs, a Leading Womens Health and Dietary Supplements Portfolio of Brands (Business Wire)
Dec-14-23 07:49AM	Dr. Reddys becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index (Business Wire)
Dec-06-23 07:00AM	Coya Therapeutics, Inc. and Dr. Reddys Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Nov-02-23 09:40AM	Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term (Zacks)
Oct-30-23 07:38AM	Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates (Zacks)
Oct-29-23 01:08PM	Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript (Insider Monkey)
Oct-27-23 02:13PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
01:50PM	Dr. Reddys Q2 FY24 Financial Results (Business Wire)
Oct-26-23 12:00PM	All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy (Zacks)
Oct-04-23 12:45PM	3 Reasons Growth Investors Will Love Doctor Reddy's (RDY) (Zacks)
Sep-26-23 09:35AM	Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-18-23 12:45PM	Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now (Zacks)
Aug-31-23 12:45PM	Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice (Zacks)
Aug-10-23 07:00AM	Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. (Business Wire)
Jul-28-23 08:02AM	Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates (Zacks)
Jul-27-23 10:30AM	Dr. Reddys Laboratories Limited (NYSE:RDY) Q1 2024 Earnings Call Transcript (Insider Monkey)
Jul-26-23 12:31PM	Dr. Reddys Q1 FY24 Financial Results (Business Wire)
Jul-12-23 10:25AM	Dr. Reddys Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA (Business Wire)
Jun-09-23 09:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Jun-08-23 09:54PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
Jun-06-23 07:18AM	10 Top-Rated Stocks Billionaires Are Loading Up On (Insider Monkey)
Jun-05-23 07:00AM	Dr. Reddys Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab (Business Wire)
Jun-04-23 03:51PM	The 3 Most Undervalued Value Stocks to Buy in June 2023 (InvestorPlace)
May-16-23 10:22AM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
May-11-23 09:58AM	Dr. Reddy's (RDY) Q4 Earnings and Revenues Beat Estimates (Zacks) -6.47%
May-10-23 11:43AM	Dr. Reddys Q4 & FY23 Financial Results (Business Wire)
09:21AM	India's Dr Reddy's Labs posts 11-fold jump in Q4 profit (Reuters)
May-08-23 01:28PM	Dr. Reddy's: A Profitable, Predictable Margin Expander (GuruFocus.com)
May-05-23 07:17AM	Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S. (Business Wire)
Apr-21-23 07:15AM	Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S. (Business Wire)
Mar-20-23 07:00AM	Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddys Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases (Business Wire)
Feb-27-23 03:04PM	Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal (Benzinga)
06:00AM	Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharmas U.S. Generic Prescription Product Portfolio (Business Wire)
Feb-08-23 08:50AM	Dr. Reddys included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Globals Sustainability Yearbook for the 3rd year (Business Wire)
Jan-31-23 06:25PM	The 3 Most Undervalued Stocks in India for Your February Buy List (InvestorPlace)
Jan-30-23 06:51PM	Analyst Report: Dr. Reddy's Laboratories Limited (Morningstar Research)
Jan-27-23 01:36PM	Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates (Zacks)
07:03AM	Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market (Business Wire)
Jan-26-23 12:55PM	Dr. Reddys Laboratories Limited (NYSE:RDY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Jan-20-23 06:30AM	Dr. Reddys successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe (Business Wire)
Dec-19-22 08:00AM	Dr. Reddys Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab (Business Wire)
Oct-31-22 11:01AM	Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2 (Zacks)
Oct-11-22 07:57AM	World Economic Forum Recognises Dr. Reddys Hyderabad Factory as Part of its Global Lighthouse Network (Business Wire)
Sep-07-22 01:28PM	Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity (Business Wire)
Aug-17-22 10:16AM	Intercept Settles Ocaliva Litigation With Reddy's Lab (Benzinga)
Aug-02-22 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jul-29-22 04:28PM	Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase (Zacks)
01:24PM	Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S. (Business Wire)
Jul-27-22 03:26AM	Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market (Business Wire)
Jul-22-22 06:17AM	Dr. Reddys Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market (Business Wire)
Jul-08-22 11:48AM	Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market (Business Wire)

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Israeli Erez	Officer	Jul 29 '24	Proposed Sale	82.29	65,500	5,390,000		Jul 29 10:55 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Dr. Reddy's Laboratories Ltd. ADR

Upgrade your FINVIZ experience